BiOasis Technologies
Provista Diagnostics has formed its scientific advisory board, appointing Karen Anderson, Carlos Arteaga, Robert Benezra, Andrew Dannenberg, and Joshua LaBaer.
Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
Premium
The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.
The assay, which uses SISCAPA MRM-MS to measure serum levels of melanotransferrin – a protein that a number of studies have tied to Alzheimer's – marks an example of mass spec-based proteomics' ongoing move into the clinical setting.
The latest pact will focus on the use of p97 as a delivery system to transport Alzheimer's drugs across the blood-brain barrier. Last month, Bioasis and UBC inked a first research collaboration to develop and test a p97-based blood test to diagnose and monitor Alzheimer's.
BiOasis Raises C$1.7M from Warrants
The Canadian firm will use the funds to support further development of its diagnostic assays for Alzheimer's disease.